Significance of Epstein-Barr Virus DNA Quantitation in Donors of Hematopoietic Stem Cell Transplantation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Epstein-Barr virus (EBV) is a well-known causative agent of various diseases including post-transplant lymphoproliferative disorders. Although the level of EBV viral load in donors is expected to have a direct effect on recipients after hematopoietic stem cell transplantation (HSCT),little has been studied providing a clear evidence for that. We performed EBV DNA quantitation in donors and analyzed the effect of donors’ EBV viral load on the recipients after HSCT. Methods : EBV DNA quantitation of peripheral blood in 94 healthy HSCT donors was performed by real-time PCR. We analyzed the distribution of EBV viral load in HSCT donors and EBV positivity in the recipients transplanted from donors who had detectable EBV. Results : Fifteen HSCT donors (16%) showed positive results in EBV real-time quantitative PCR. EBV viral load was below 500 copies/mL in 5 donors and above 500 (680-11,300) copies/mL in 10 donors. Five of the recipients (33.3%) transplanted from these 15 donors showed positivity in EBV PCR after HSCT. All of the EBV PCR positive recipients were transplanted from donors with viral load of >1,000 copies/mL, and 5 (71%) of 7 donors with viral load of >1,000 copies/mL was associated with posttansplant EBV PCR positivity in the recipients. Conclusions : Higher levels of EBV viral load in donors appear to be associated with EBV transmission to recipients in HSCT. EBV real-time quantitative PCR may be needed for screening EBV DNA level in HSCT donors. (Korean J Lab Med 2010;30:554-8)
Abstract
Background : Epstein-Barr virus (EBV) is a well-known causative agent of various diseases including post-transplant lymphoproliferative disorders. Although the level of EBV viral load in donors is expected to have a direct effect on recipients after hematopoietic stem cell transplantation (HSCT),little has been studied providing a clear evidence for that. We performed EBV DNA quantitation in donors and analyzed the effect of donors’ EBV viral load on the recipients after HSCT. Methods : EBV DNA quantitation of peripheral blood in 94 healthy HSCT donors was performed by real-time PCR. We analyzed the distribution of EBV viral load in HSCT donors and EBV positivity in the recipients transplanted from donors who had detectable EBV. Results : Fifteen HSCT donors (16%) showed positive results in EBV real-time quantitative PCR. EBV viral load was below 500 copies/mL in 5 donors and above 500 (680-11,300) copies/mL in 10 donors. Five of the recipients (33.3%) transplanted from these 15 donors showed positivity in EBV PCR after HSCT. All of the EBV PCR positive recipients were transplanted from donors with viral load of >1,000 copies/mL, and 5 (71%) of 7 donors with viral load of >1,000 copies/mL was associated with posttansplant EBV PCR positivity in the recipients. Conclusions : Higher levels of EBV viral load in donors appear to be associated with EBV transmission to recipients in HSCT. EBV real-time quantitative PCR may be needed for screening EBV DNA level in HSCT donors. (Korean J Lab Med 2010;30:554-8)
참고문헌 (13)
- Weinstock DM, "Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development", Bone Marrow Transplant, 37, pp.539~546 (2006)
- Schäfer H, "Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprinting", Transplantation, 72, pp.492~496 (2001)
- Shapiro RS, "Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation", Blood, 71, pp.1234~1243 (1988)
- Zutter MM, "Epstein-Barr virus lymphoproliferation after bone marrow transplantation", Blood, 72, pp.520~529 (1988)
- Gratama JW, "Epstein-Barr virus infection in allogeneic marrow grafting: lessons for transplant physicians and virologists", Ann Hematol, 64(S), pp.A162~A165 (1992)
- Haque T, "Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients", J Gen Virol, 77, pp.1169~1172 (1996)
- Lin JC, "Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival", J Clin Oncol, 19, pp.2607~2615 (2001)
- van Esser JW, "Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation", Blood, 99, pp.4364~4369 (2002)
- Gottschalk S, "Post-transplant lymphoproliferative disorders", Annu Rev Med, 56, pp.29~44 (2005)
- Lange B, "Epstein-Barr virus-related serology in marrow transplant recipient", Int J Cancer, 26, pp.151~157 (1980)
- Lee ES, "The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation", N Engl J Med, 332, pp.19~25 (1995)
- Collins MH, "Metachronous Epstein-Barr virus-related smooth muscle tumors in a child after heart transplantation: case report and review of the literature", J Pediatr Surg, 36, pp.1452~1455 (2001)
- Bitan M, "Early-onset Guillain-Barre syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation", Clin Infect Dis, 39, pp.1076~1078 (2004)